Targets & Mechanisms
Triplet brings a new strategy to Huntington’s disease
Unveils preclinical POC data for its first DNA damage repair target
Triplet unveils preclinical proof-of-concept data in Huntington’s disease for the company’s first DNA damage repair target.
Preclinical data suggest that with a new target and route of administration, Triplet’s antisense oligonucleotide for Huntington’s disease may be effective where others have fallen short.
The Cambridge, Mass.-based company unveiled preclinical data for its first target — DNA damage repair gene MSH3 — at